60 Degrees Pharmaceuticals Statistics
Share Statistics
60 Degrees Pharmaceuticals has 2.30M shares outstanding. The number of shares has increased by -67.9% in one year.
Shares Outstanding | 2.30M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | -84.75% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.91M |
Failed to Deliver (FTD) Shares | 2.07K |
FTD / Avg. Volume | 0.76% |
Short Selling Information
The latest short interest is 37.30K, so 1.62% of the outstanding shares have been sold short.
Short Interest | 37.30K |
Short % of Shares Out | 1.62% |
Short % of Float | 1.93% |
Short Ratio (days to cover) | 0.34 |
Valuation Ratios
The PE ratio is -12.87 and the forward PE ratio is -0.55.
PE Ratio | -12.87 |
Forward PE | -0.55 |
PS Ratio | 191.16 |
Forward PS | 1.2 |
PB Ratio | 9.95 |
P/FCF Ratio | -10.4 |
PEG Ratio | n/a |
Enterprise Valuation
60 Degrees Pharmaceuticals Inc. has an Enterprise Value (EV) of 3.96M.
EV / Earnings | -1.05 |
EV / Sales | 15.6 |
EV / EBITDA | -2.77 |
EV / EBIT | -0.77 |
EV / FCF | -0.85 |
Financial Position
The company has a current ratio of 2.55, with a Debt / Equity ratio of 0.03.
Current Ratio | 2.55 |
Quick Ratio | 2.39 |
Debt / Equity | 0.03 |
Total Debt / Capitalization | 3.16 |
Cash Flow / Debt | -28.57 |
Interest Coverage | -2.25 |
Financial Efficiency
Return on equity (ROE) is -0.77% and return on capital (ROIC) is -103.7%.
Return on Equity (ROE) | -0.77% |
Return on Assets (ROA) | -0.48% |
Return on Capital (ROIC) | -103.7% |
Revenue Per Employee | 84.52K |
Profits Per Employee | -1.26M |
Employee Count | 3 |
Asset Turnover | 0.03 |
Inventory Turnover | 1.02 |
Taxes
Income Tax | 250 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.55% in the last 52 weeks. The beta is 5.27, so 60 Degrees Pharmaceuticals 's price volatility has been higher than the market average.
Beta | 5.27 |
52-Week Price Change | -83.55% |
50-Day Moving Average | 1.05 |
200-Day Moving Average | 2.2 |
Relative Strength Index (RSI) | 54.04 |
Average Volume (20 Days) | 270.86K |
Income Statement
In the last 12 months, 60 Degrees Pharmaceuticals had revenue of $253.57K and earned -$3.77M in profits. Earnings per share was $-0.95.
Revenue | 253.57K |
Gross Profit | -220.98K |
Operating Income | -5.15M |
Net Income | -3.77M |
EBITDA | -1.43M |
EBIT | -5.15M |
Earnings Per Share (EPS) | -0.95 |
Balance Sheet
The company has $2.14M in cash and $172.67K in debt, giving a net cash position of $1.97M.
Cash & Cash Equivalents | 2.14M |
Total Debt | 172.67K |
Net Cash | 1.97M |
Retained Earnings | -32.58M |
Total Assets | 7.42M |
Working Capital | 5.58M |
Cash Flow
In the last 12 months, operating cash flow was -$4.54M and capital expenditures -$115.89K, giving a free cash flow of -$4.66M.
Operating Cash Flow | -4.54M |
Capital Expenditures | -115.89K |
Free Cash Flow | -4.66M |
FCF Per Share | -1.18 |
Margins
Gross margin is -87.15%, with operating and profit margins of -2.03K% and -1.49K%.
Gross Margin | -87.15% |
Operating Margin | -2.03K% |
Pretax Margin | -1.50K% |
Profit Margin | -1.49K% |
EBITDA Margin | -562.58% |
EBIT Margin | -2.03K% |
FCF Margin | -1.84K% |
Dividends & Yields
SXTP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -68.84% |
FCF Yield | -146.94% |
Analyst Forecast
Currently there are no analyst rating for SXTP.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 12, 2024. It was a backward split with a ratio of 1:12.
Last Split Date | Aug 12, 2024 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | -8.27 |
Piotroski F-Score | 6 |